The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gene Modifying Immunotherapy for Blood Cancer Market Research Report 2025
Synopsis
Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.
The global Gene Modifying Immunotherapy for Blood Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Gene Modifying Immunotherapy for Blood Cancer in Acute Lymphocytic Leukemia is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Gene Modifying Immunotherapy for Blood Cancer include Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals and Mustang Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gene Modifying Immunotherapy for Blood Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Modifying Immunotherapy for Blood Cancer.
Report Scope
The Gene Modifying Immunotherapy for Blood Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Modifying Immunotherapy for Blood Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Modifying Immunotherapy for Blood Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio
Segment by Type
CAR T-cell Therapy
TCR T-cell Therapy
Segment by Application
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Modifying Immunotherapy for Blood Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.
The global Gene Modifying Immunotherapy for Blood Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Gene Modifying Immunotherapy for Blood Cancer in Acute Lymphocytic Leukemia is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Gene Modifying Immunotherapy for Blood Cancer include Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals and Mustang Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gene Modifying Immunotherapy for Blood Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Modifying Immunotherapy for Blood Cancer.
Report Scope
The Gene Modifying Immunotherapy for Blood Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Modifying Immunotherapy for Blood Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Modifying Immunotherapy for Blood Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio
Segment by Type
CAR T-cell Therapy
TCR T-cell Therapy
Segment by Application
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Modifying Immunotherapy for Blood Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CAR T-cell Therapy
1.2.3 TCR T-cell Therapy
1.3 Market by Application
1.3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Acute Lymphocytic Leukemia
1.3.3 Chronic Lymphocytic Leukemia
1.3.4 B Cell Lymphoma
1.3.5 Multiple Myeloma
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Perspective (2019-2030)
2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Region
2.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Region (2019-2024)
2.2.3 Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Region (2025-2030)
2.3 Gene Modifying Immunotherapy for Blood Cancer Market Dynamics
2.3.1 Gene Modifying Immunotherapy for Blood Cancer Industry Trends
2.3.2 Gene Modifying Immunotherapy for Blood Cancer Market Drivers
2.3.3 Gene Modifying Immunotherapy for Blood Cancer Market Challenges
2.3.4 Gene Modifying Immunotherapy for Blood Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue
3.1.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue (2019-2024)
3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Modifying Immunotherapy for Blood Cancer Revenue
3.4 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio
3.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2023
3.5 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
3.6 Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
3.7 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Type
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2019-2024)
4.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2025-2030)
5 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Application
5.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Application (2019-2024)
5.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
6.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
6.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
7.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
8.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
9.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
9.4 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
10.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Kite Pharma
11.2.1 Kite Pharma Company Detail
11.2.2 Kite Pharma Business Overview
11.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Introduction
11.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.2.5 Kite Pharma Recent Development
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics Company Detail
11.3.2 Juno Therapeutics Business Overview
11.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Introduction
11.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.3.5 Juno Therapeutics Recent Development
11.4 Cellectis
11.4.1 Cellectis Company Detail
11.4.2 Cellectis Business Overview
11.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.4.5 Cellectis Recent Development
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Detail
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.5.5 Ziopharm Oncology Recent Development
11.6 Celyad
11.6.1 Celyad Company Detail
11.6.2 Celyad Business Overview
11.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Introduction
11.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.6.5 Celyad Recent Development
11.7 Bluebird Bio
11.7.1 Bluebird Bio Company Detail
11.7.2 Bluebird Bio Business Overview
11.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.7.5 Bluebird Bio Recent Development
11.8 Bellicum Pharmaceuticals
11.8.1 Bellicum Pharmaceuticals Company Detail
11.8.2 Bellicum Pharmaceuticals Business Overview
11.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Introduction
11.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.8.5 Bellicum Pharmaceuticals Recent Development
11.9 Mustang Bio
11.9.1 Mustang Bio Company Detail
11.9.2 Mustang Bio Business Overview
11.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.9.5 Mustang Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
